The Cole Relaxation Frequency as a Parameter to Identify Cancer in Lung Tissue: Preliminary Animal and Ex Vivo Patient Studies
BackgroundLung cancer is the world’s leading cause of cancer deaths, and diagnosis remains challenging. Lung cancer starts as small nodules; early and accurate diagnosis allows timely surgical resection of malignant nodules while avoiding unnecessary surgery in patients with...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
JMIR Publications
2022-02-01
|
| Series: | JMIR Biomedical Engineering |
| Online Access: | https://biomedeng.jmir.org/2022/1/e35346 |
| _version_ | 1797735340800212992 |
|---|---|
| author | Les Bogdanowicz Onur Fidaner Donato Ceres Alexander Grycuk Martina Guidetti David Demos |
| author_facet | Les Bogdanowicz Onur Fidaner Donato Ceres Alexander Grycuk Martina Guidetti David Demos |
| author_sort | Les Bogdanowicz |
| collection | DOAJ |
| description |
BackgroundLung cancer is the world’s leading cause of cancer deaths, and diagnosis remains challenging. Lung cancer starts as small nodules; early and accurate diagnosis allows timely surgical resection of malignant nodules while avoiding unnecessary surgery in patients with benign nodules.
ObjectiveThe Cole relaxation frequency (CRF) is a derived electrical bioimpedance signature, which may be utilized to distinguish cancerous tissues from normal tissues.
MethodsHuman testing ex vivo was conducted with NoduleScan in freshly resected lung tissue from 30 volunteer patients undergoing resection for nonsmall cell lung cancer. The CRF of the tumor and the distant normal lung tissue relative to the tumor were compared to histopathology specimens to establish a potential algorithm for point-of-care diagnosis. For animal testing in vivo, 20 mice were implanted with xenograft human lung cancer tumor cells injected subcutaneously into the right flank of each mouse. Spectral impedance measurements were taken on the tumors on live animals transcutaneously and on the tumors after euthanasia. These CRF measurements were compared to healthy mouse lung tissue. For porcine lung testing ex vivo, porcine lungs were received with the trachea. After removal of the vocal box, a ventilator was attached to pressurize the lung and simulate breathing. At different locations of the lobes, the lung's surface was cut to produce a pocket that could accommodate tumors obtained from in vivo animal testing. The tumors were placed in the subsurface of the lung, and the electrode was placed on top of the lung surface directly over the tumor but with lung tissue between the tumor and the electrode. Spectral impedance measurements were taken when the lungs were in the deflated state, inflated state, and also during the inflation-deflation process to simulate breathing.
ResultsAmong 60 specimens evaluated in 30 patients, NoduleScan allowed ready discrimination in patients with clear separation of CRF in tumor and distant normal tissue with a high degree of sensitivity (97%) and specificity (87%). In the 25 xenograft small animal model specimens measured, the CRF aligns with the separation observed in the human in vivo measurements. The CRF was successfully measured of tumors implanted into ex vivo porcine lungs, and CRF measurements aligned with previous tests for pressurized and unpressurized lungs.
ConclusionsAs previously shown in breast tissue, CRF in the range of 1kHz-10MHz was able to distinguish nonsmall cell lung cancer versus normal tissue. Further, as evidenced by in vivo small animal studies, perfused tumors have the same CRF signature as shown in breast tissue and human ex vivo testing. Inflation and deflation of the lung have no effect on the CRF signature. With additional development, CRF derived from spectral impedance measurements may permit point-of-care diagnosis guiding surgical resection. |
| first_indexed | 2024-03-12T12:56:37Z |
| format | Article |
| id | doaj.art-7f078e5840d145579097c1953518c6ef |
| institution | Directory Open Access Journal |
| issn | 2561-3278 |
| language | English |
| last_indexed | 2024-03-12T12:56:37Z |
| publishDate | 2022-02-01 |
| publisher | JMIR Publications |
| record_format | Article |
| series | JMIR Biomedical Engineering |
| spelling | doaj.art-7f078e5840d145579097c1953518c6ef2023-08-28T20:50:49ZengJMIR PublicationsJMIR Biomedical Engineering2561-32782022-02-0171e3534610.2196/35346The Cole Relaxation Frequency as a Parameter to Identify Cancer in Lung Tissue: Preliminary Animal and Ex Vivo Patient StudiesLes Bogdanowiczhttps://orcid.org/0000-0003-1342-4454Onur Fidanerhttps://orcid.org/0000-0001-7121-1882Donato Cereshttps://orcid.org/0000-0002-4533-3373Alexander Grycukhttps://orcid.org/0000-0002-9188-5005Martina Guidettihttps://orcid.org/0000-0001-8882-4386David Demoshttps://orcid.org/0000-0001-9866-550X BackgroundLung cancer is the world’s leading cause of cancer deaths, and diagnosis remains challenging. Lung cancer starts as small nodules; early and accurate diagnosis allows timely surgical resection of malignant nodules while avoiding unnecessary surgery in patients with benign nodules. ObjectiveThe Cole relaxation frequency (CRF) is a derived electrical bioimpedance signature, which may be utilized to distinguish cancerous tissues from normal tissues. MethodsHuman testing ex vivo was conducted with NoduleScan in freshly resected lung tissue from 30 volunteer patients undergoing resection for nonsmall cell lung cancer. The CRF of the tumor and the distant normal lung tissue relative to the tumor were compared to histopathology specimens to establish a potential algorithm for point-of-care diagnosis. For animal testing in vivo, 20 mice were implanted with xenograft human lung cancer tumor cells injected subcutaneously into the right flank of each mouse. Spectral impedance measurements were taken on the tumors on live animals transcutaneously and on the tumors after euthanasia. These CRF measurements were compared to healthy mouse lung tissue. For porcine lung testing ex vivo, porcine lungs were received with the trachea. After removal of the vocal box, a ventilator was attached to pressurize the lung and simulate breathing. At different locations of the lobes, the lung's surface was cut to produce a pocket that could accommodate tumors obtained from in vivo animal testing. The tumors were placed in the subsurface of the lung, and the electrode was placed on top of the lung surface directly over the tumor but with lung tissue between the tumor and the electrode. Spectral impedance measurements were taken when the lungs were in the deflated state, inflated state, and also during the inflation-deflation process to simulate breathing. ResultsAmong 60 specimens evaluated in 30 patients, NoduleScan allowed ready discrimination in patients with clear separation of CRF in tumor and distant normal tissue with a high degree of sensitivity (97%) and specificity (87%). In the 25 xenograft small animal model specimens measured, the CRF aligns with the separation observed in the human in vivo measurements. The CRF was successfully measured of tumors implanted into ex vivo porcine lungs, and CRF measurements aligned with previous tests for pressurized and unpressurized lungs. ConclusionsAs previously shown in breast tissue, CRF in the range of 1kHz-10MHz was able to distinguish nonsmall cell lung cancer versus normal tissue. Further, as evidenced by in vivo small animal studies, perfused tumors have the same CRF signature as shown in breast tissue and human ex vivo testing. Inflation and deflation of the lung have no effect on the CRF signature. With additional development, CRF derived from spectral impedance measurements may permit point-of-care diagnosis guiding surgical resection.https://biomedeng.jmir.org/2022/1/e35346 |
| spellingShingle | Les Bogdanowicz Onur Fidaner Donato Ceres Alexander Grycuk Martina Guidetti David Demos The Cole Relaxation Frequency as a Parameter to Identify Cancer in Lung Tissue: Preliminary Animal and Ex Vivo Patient Studies JMIR Biomedical Engineering |
| title | The Cole Relaxation Frequency as a Parameter to Identify Cancer in Lung Tissue: Preliminary Animal and Ex Vivo Patient Studies |
| title_full | The Cole Relaxation Frequency as a Parameter to Identify Cancer in Lung Tissue: Preliminary Animal and Ex Vivo Patient Studies |
| title_fullStr | The Cole Relaxation Frequency as a Parameter to Identify Cancer in Lung Tissue: Preliminary Animal and Ex Vivo Patient Studies |
| title_full_unstemmed | The Cole Relaxation Frequency as a Parameter to Identify Cancer in Lung Tissue: Preliminary Animal and Ex Vivo Patient Studies |
| title_short | The Cole Relaxation Frequency as a Parameter to Identify Cancer in Lung Tissue: Preliminary Animal and Ex Vivo Patient Studies |
| title_sort | cole relaxation frequency as a parameter to identify cancer in lung tissue preliminary animal and ex vivo patient studies |
| url | https://biomedeng.jmir.org/2022/1/e35346 |
| work_keys_str_mv | AT lesbogdanowicz thecolerelaxationfrequencyasaparametertoidentifycancerinlungtissuepreliminaryanimalandexvivopatientstudies AT onurfidaner thecolerelaxationfrequencyasaparametertoidentifycancerinlungtissuepreliminaryanimalandexvivopatientstudies AT donatoceres thecolerelaxationfrequencyasaparametertoidentifycancerinlungtissuepreliminaryanimalandexvivopatientstudies AT alexandergrycuk thecolerelaxationfrequencyasaparametertoidentifycancerinlungtissuepreliminaryanimalandexvivopatientstudies AT martinaguidetti thecolerelaxationfrequencyasaparametertoidentifycancerinlungtissuepreliminaryanimalandexvivopatientstudies AT daviddemos thecolerelaxationfrequencyasaparametertoidentifycancerinlungtissuepreliminaryanimalandexvivopatientstudies AT lesbogdanowicz colerelaxationfrequencyasaparametertoidentifycancerinlungtissuepreliminaryanimalandexvivopatientstudies AT onurfidaner colerelaxationfrequencyasaparametertoidentifycancerinlungtissuepreliminaryanimalandexvivopatientstudies AT donatoceres colerelaxationfrequencyasaparametertoidentifycancerinlungtissuepreliminaryanimalandexvivopatientstudies AT alexandergrycuk colerelaxationfrequencyasaparametertoidentifycancerinlungtissuepreliminaryanimalandexvivopatientstudies AT martinaguidetti colerelaxationfrequencyasaparametertoidentifycancerinlungtissuepreliminaryanimalandexvivopatientstudies AT daviddemos colerelaxationfrequencyasaparametertoidentifycancerinlungtissuepreliminaryanimalandexvivopatientstudies |